Previous Close | 131.75 |
Open | 132.00 |
Bid | 132.05 x 1200 |
Ask | 132.17 x 1000 |
Day's Range | 131.41 - 132.42 |
52 Week Range | 99.14 - 133.10 |
Volume | |
Avg. Volume | 8,735,054 |
Market Cap | 332.954B |
Beta (5Y Monthly) | 0.38 |
PE Ratio (TTM) | 939.04 |
EPS (TTM) | 0.14 |
Earnings Date | Apr 25, 2024 |
Forward Dividend & Yield | 3.08 (2.34%) |
Ex-Dividend Date | Mar 14, 2024 |
1y Target Est | 136.06 |
Subscribe to Yahoo Finance Plus to view Fair Value for MRK
The Food and Drug Administration has approved Winrevair, Merck's (MRK) latest drug to treat pulmonary arterial hypertension, a lung condition. Investors have been anxiously awaiting the approval as the company is set to lose its patent for Keytruda. The drug will help to reduce the risk of death and worsening events in patients by 84%. Yahoo Finance's Anjalee Khemlani joins The Morning Brief to discuss how the treatment could offer a potential path to the upside for Merck. For more expert insight and the latest market action, click here to watch this full episode of Market Domination. Editor's Note: This article was written by Gabriel Roy
Two Merck leaders share how their company is working to help protect communities from vaccine-preventable illnesses NORTHAMPTON, MA / ACCESSWIRE / March 28, 2024 / Vaccines are one of the most significant public health achievements in modern history, ...